High-powered holmium and thulium laser platforms are expanding ureteroscopic options for complex patients, including those on anticoagulation, while emerging technologies such as Break Wave ...
Neha Vapiwala, MD, pointed to the shift toward more personalized approaches and the expanding role of radiopharmaceutical therapies. In the following video, Neha Vapiwala, MD, FASTRO, outlines key ...
LITESPARK-011 randomized patients 1:1 to belzutifan/lenvatinib versus cabozantinib, using dual primary endpoints of PFS and OS across 184 global sites. Efficacy improvements included higher ORR and ...
FDA approved Gozellix for prostate cancer imaging and expanded 177Lu-PSMA-617's label for mCRPC treatment. 64Cu-SAR-bisPSMA demonstrated efficacy in detecting recurrent prostate cancer in the COBRA ...
Explore the latest long-term data on abiraterone and enzalutamide, revealing survival benefits and safety insights for prostate cancer treatments.
"Based on the code description, we recommend basing the code selection on the documentation and the effort required to complete the service, and not the number of foreign bodies removed from the ...
ORIC-944 demonstrated significant anti-tumor activity and tolerability in combination with ARPIs in mCRPC patients. The phase 1b trial showed notable PSA and ctDNA reductions across all ORIC-944 dose ...
Martin M. Miner, MD, highlights key findings from TRAVERSE and the T4DM study. Miner is the co-director of the men’s health center at Brown University Health in Providence, Rhode Island. Miner began ...
The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled ...
VIR-5500 targets PSMA and is being tested in a phase 1 trial for mCRPC, including combination therapy with ARPIs. Interim data showed PSA reductions in all patients and a favorable safety profile, ...
The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...
Sunobinop showed significant symptom improvement in 41% of IC/BPS patients versus 9% with placebo, indicating its potential efficacy. The investigational compound targets the NOP receptor, affecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results